A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach
- PMID: 34866201
- DOI: 10.1111/apt.16720
A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent condition that requires a comprehensive and coordinated response across sectors and disciplines.
Aims: In the absence of a multisectoral framework to tackle this condition, we developed one using the sustainable development goals (SDGs) as the basis for converging thinking about the design and delivery of public health responses.
Methods: A multidisciplinary group identified the SDG targets and indicators for inclusion in the new framework through a two-stage process. Firstly, a core team of three researchers independently reviewed the 169 targets and 231 indicators of the SDGs to select a shortlist. Over two Delphi rounds, a multidisciplinary group of 12 experts selected which of the shortlisted targets and indicators to include. Respondents also provided written feedback on their selection. Targets and indicators with 75% or greater agreement were included in the final framework.
Results: The final framework comprises 16 targets-representing 9% of all targets and 62% (16/26) of the shortlisted targets-and seven indicators, accounting for 50% (7/14) of the shortlisted indicators and 3% of all indicators. The selected targets and indicators cover a broad range of factors, from health, food and nutrition to education, the economy, and the built environment.
Conclusions: Addressing the challenge of NAFLD will require a re-envisioning of the liver health landscape, with greater focus on joined-up systems thinking and action. This new framework can help guide this process, including by outlining the stakeholders with whom the liver health community needs to engage.
© 2021 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Comment in
-
Editorial: global liver fat accumulation and global health-towards a sustainable development goal.Aliment Pharmacol Ther. 2022 Feb;55(4):487-488. doi: 10.1111/apt.16750. Aliment Pharmacol Ther. 2022. PMID: 35092044 No abstract available.
-
Editorial: global liver fat accumulation and global health-towards a sustainable development goal. Authors' reply.Aliment Pharmacol Ther. 2022 Feb;55(4):489-490. doi: 10.1111/apt.16768. Aliment Pharmacol Ther. 2022. PMID: 35092059 No abstract available.
-
Editorial: chronic hepatitis C with metabolic dysfunction-associated fatty liver disease - a model for adoption of Sustainable Development Goal 3.Aliment Pharmacol Ther. 2023 Jan;57(2):270-271. doi: 10.1111/apt.17270. Epub 2022 Dec 5. Aliment Pharmacol Ther. 2023. PMID: 36468204 No abstract available.
References
REFERENCES
-
- Rutter H, Savona N, Glonti K, et al. The need for a complex systems model of evidence for public health. Lancet. 2017;390:2602-2604.
-
- Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84.
-
- Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204-1222.
-
- Huber Y, Boyle M, Hallsworth K, et al. Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clin Gastroenterol Hepatol. 2019;17:2085-2092.e1.
-
- Schattenberg JM, Lazarus JV, Newsome PN, et al. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in five European countries in 2018: a cost-of-illness analysis. Liver Int. 2021;41:1227-1242.
